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Correlation between serum methotrexate concentrations and disease remission status in rheumatoid arthritis patients on triple disease-modifying antirheumatic drug therapy
The therapeutic goals in rheumatoid arthritis (RA) are the patients attending the Rheumatology Clinic were recruited after induction of remission of symptoms involving the joints, a return obtaining their written informed consent and approval from the of full function and the maintenance of remission with diseaseinstitutional ethics committee. All patients fulfilled the American modifying antirheumatic drugs (DMARDs). The current strategy College of Rheumatology (ACR) criteria for RA but without is initial aggressive treatment with a combination of DMARDs to any significant systemic involvement secondary to RA (e.g., prevent substantial disability and premature mortality. One such Vasculitis, Pulmonary fibrosis etc.). Six patients had DAS28-3 synthetic DMARD, methotrexate (MTX), is known to induce a < 2.66 (1.48 ± 0.1) and the other six had DAS28-3 scores > long-term response.
[1] Low-dose methotrexate (LDMTX), 5-17.5 2.66 (3.99 ± 0.99). All patients received triple DMARD therapy, mg/week, [1] is given in combination with sulfasalazine and/or i.e., Tab Methotrexate 10 mg/week, Tab Sulfasalazine 1 gm bid hydroxychloroquine. Even with combination therapy, more and Tab Hydroxychloroquine 200 mg hs od on an out patient than one third of the patients fail to achieve remission due to basis. The patients were also taking proton pump inhibitors, unknown reasons. Thus, it seems to be possible to individualise folinic acid and naproxen. Patient characteristics are given in LDMTX therapy according to the results of pharmacokinetic and Table 1 . To assess the remission status, disease activity scores pharmacodynamic analysis.
(DAS28-3) were calculated using the results of the 28 tender joint Based on these observations, we decided to conduct an initial count (TJC 28), 28 swollen joint count (SJC 28) and erythrocyte pilot study to estimate serum MTX concentrations and their effect sedimentation rate (ESR, 60 min) based on the formula given on disease remission status in RA patients on triple DMARD by Fransen et al. [2] therapy. As the measurement of serum MTX is expensive (Rs. DAS28-3 < 2.66 results in the fulfilment of preliminary 630/sample in our institution), we planned to conduct our study American Rheumatism Association (ARA) criteria for clinical in two phases, a pilot followed by (if necessary) a definitive phase remission in RA. [2] in case the pilot study revealed a correlation between disease Two blood samples were collected, before and 1.5 hrs after remission and serum drug concentrations. At this juncture, 10 mg Tab Methotrexate intake. Serum was extracted and stored we would like to acknowledge that correlating serum MTX at -70 C until analysis. The cycle of methotrexate intake by the concentration alone with disease remission status in patients patients was unaltered during the study. Serum methotrexate taking many drugs, is a limitation in our study. However, given concentrations were estimated based on the enzyme-multiplied that MTX is the chief component of the triple regimen and that it immunoassay technique (EMIT) as described by Oellerich et al. has both toxicity and interindividual variability in bioavailability, EMIT was performed using the Hitachi 912 auto analyzer and it continues to be a very important aspect of LDMTX therapy MTX kits were purchased from Syva Company, Dade Boehring The study was conducted at Christian Medical College, Vellore, Inc., GmbH. The assay was optimized for measuring MTX with India between April 2005 to October 2005. Twelve female RA a standard curve ranging from 0.1-2.0 µmol/liter.
[3] populations in western countries reported a lack of correlation between serum MTX concentrations and disease activity status, [4, 5] the data is still not enough to fully accept or refute therapeutic drug monitoring of MTX in LDMTX regimens in RA. Our study shows an insignificant correlation between serum methotrexate concentrations and disease remission status. Genetic polymorphisms are predicted to influence the clinical response to LDMTX.
[1] Hence, it is possible that there will be an interracial difference in the clinical efficacy of LDMTX. To the best of our knowledge, inspite of seven million Indians reported to be suffering from RA and a large number of RA Patients with DAS scores > 2.66 patients receiving LDMTX due to its efficacy and low cost, no pharmacokinetics data on LDMTX in Indian RA patients is Patients with DAS scores < 2.66 available. Thus, although our study has been conducted in a small number of Indian patients (twelve), it strengthens the view that routine monitoring of MTX concentrations in RA patients on LDMTX are not essential as they are expensive and for MTX PK in Indian RA patients.
The Mann Whitney test was used for statistical analysis. P Acknowledgments value < 0.05 was considered to be statistically significant. The within the normal range. may be as low as 25% and as high as 100% (mean 70%). 
